Ítem
Acceso Abierto

Relación entre el conteo plaquetario y linfocitario y la sobrevida en pacientes menores de 18 años con trasplante alogénico de células madre hematopoyéticas

Mostrar el registro sencillo de la publicación
dc.contributor.advisorAponte Barrios, Nelson Hernando
dc.creatorChavarriaga Ruíz, Nataly
dc.creatorEstupiñan Calvache, Marcela
dc.creatorVallejo Rosero, Cristian
dc.creatorCastañeda Figueroa, Ana Maria
dc.creator.degreeEspecialista en Epidemiología (en Convenio con el CES)spa
dc.creator.degreetypeFull timespa
dc.date.accessioned2020-06-16T18:45:33Z
dc.date.available2020-06-16T18:45:33Z
dc.date.created2020-06-12
dc.descriptionIntroducción: El trasplante de células madre hematopoyéticas (SCHT) se utiliza para reestablecer la función hematopoyética en pacientes con alteración o daño en la médula ósea; en pediatría se realiza el 20% del total de estos procedimientos. La reconstitución inmunológica y el recuento plaquetario posterior al trasplante se relaciona con mejor o peor pronóstico, recaída de la enfermedad y la sobrevida. Objetivos: Evaluar la asociación entre el conteo plaquetario y linfocitario, la supervivencia general y libre de evento en una unidad de trasplantes pediátrica con trasplante alogénico por enfermedades hematooncológicas e inmunodeficiencia Metodología: Estudio analítico observacional de cohorte retrospectiva, se incluyeron 124 pacientes menores de 18 años a quien se les realizó trasplante alogénico de células madre hematopoyéticas entre 2010 a 2016 en el Hospital Pediátrico de la Misericordia, los pacientes que sobrevivieron sin recaída al día 100 se les cuantificó conteo de plaquetas y linfocitos y se siguieron hasta 3 años. Resultados: La probabilidad de supervivencia en pacientes con linfocitos <1000 al año fue de 75,36% (IC 95% 64,51-88,03%), a los dos años fue de 58,6% (IC 95% 46,45-74,08%) y a los tres años fue de 52,21% (IC 95% 39,9-68,2%) vs de 85,4% (IC 95% 77-94,7%) de 77% (IC 95% 67,1-88,4%) de 71,9% (IC 95% 61,4-84,2%) para el grupo con >1000 linfocitos respectivamente (Log-Rank=0,037). La media de supervivencia para los pacientes con plaquetas <100.000 fue de 35.2 meses (+/-3.17) y para quienes tuvieron plaquetas >100.000 fue de 39,3 meses (+/- 2.19) p=0.19. La trombocitopenia tiene se relacion con desarrollo de IECH aguda p=0,001. Discusión: El conteo absoluto de linfocitos al día 100 post trasplante es un factor independiente que afecta directamente la sobrevida de los pacientes.spa
dc.description.abstractIntroduction: Hematopoietic stem cell transplantation (SCHT) is used to reestablish hematopoietic function in patients with impaired or damaged bone marrow. In pediatrics 20% of these procedures are performed. Both immune reconstitution and post-transplant platelet count have been shown to be associated with better or worse prognosis, disease relapse, and overall survival. Objective: To assess the association between platelet and lymphocyte count, overall survival, and event-free survival in a pediatric transplant unit with allogeneic transplantation for haemato-oncological diseases and immunodeficiency. Materials and methods: Retrospective observational analytical cohort study, 124 patients under 18 years of age who underwent allogeneic hematopoietic stem cell transplantation between 2010 and 2016 at the Pediatric Hospital of La Misericordia were included; patients who survived without relapse on day 100 were quantified platelet and lymphocyte count and followed up to 3 years. Results: The probability of survival in patients with lymphocytes <1000 a year was 75.36% (95% CI 64.51-88.03%), after two years it was 58.6% (95% CI 46, 45-74.08%) and at three years it was 52.21% (95% CI 39.9-68.2%) vs 85.4% (95% CI 77-94.7%) 77% (95% CI 67.1-88.4%) of 71.9% (95% CI 61.4-84.2%) for the group with> 1000 lymphocytes respectively (Log-Rank = 0.037). The mean survival for patients with platelets <100,000 was 35.2 months (+/- 3.17) and for those with platelets> 100,000 it was 39.3 months (+/- 2.19) p = 0.19. Thrombocytopenia is related to development of acute IECH p = 0.001. Conclusion: The absolute lymphocyte count at day 100 post transplant is an independent factor that directly affects the survival of patients.spa
dc.description.embargo2020-06-16 13:50:01: Script de automatizacion de embargos. Correo recibido: Cristian Vallejo <cristian_gv@hotmail.com> Vie 12/06/2020 5:55 PM Cordial Saludo. Por medio de este medio solicito el embargo por un periodo de dos años del trabajo de grado “ Relación entre el conteo plaquetario y linfocitario y la sobreviva en pacientes menores de 18 años con trasplante alogénico de células madre hematopoyéticas” que se presentó para optar el titulo de especialista en epidemiología. La razón es que que al ser un trabajo original será mandado a una revistar para su publicación. Gracias. Quedo atento a la solicitud. - Respuesta: Repositorio Institucional EdocUR Mar 16/06/2020 1:48 PM Respetado Cristian Vallejo, reciba un cordial saludo, Hemos realizado la publicación de su documento "Relación entre el conteo plaquetario y linfocitario y la sobrevida en pacientes menores de 18 años con trasplante alogénico de células madre hematopoyéticas", el cual puede consultar en el siguiente enlace: https://repository.urosario.edu.co/handle/10336/25181 De acuerdo con su solicitud, el documento ha quedado embargado hasta el 2022-06-16 en concordancia con las Políticas de Acceso Abierto de la Universidad. Si usted desea dejarlo con acceso abierto antes de finalizar dicho periodo o si por el contrario desea extender el embargo al finalizar este tiempo, puede enviar un correo a esta misma dirección realizando la solicitud. Tenga en cuenta que los documentos en acceso abierto propician una mayor visibilidad de su producción académica. Quedamos atentos a cualquier inquietud o sugerencia
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_25181
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/25181
dc.language.isospaspa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de medicinaspa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationAppelbaum FR. Hematopoietic-Cell Transplantation at 50. N Engl J Med [Internet]. 2007 Oct 11 [cited 2020 Jun 1];357(15):1472–5. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMp078166spa
dc.source.bibliographicCitationCopelan EA. Hematopoietic Stem-Cell Transplantation. N Engl J Med [Internet]. 2006 Apr 27 [cited 2020 Jun 1];354(17):1813–26. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra052638spa
dc.source.bibliographicCitationGratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010 Apr 28;303(16):1617–24spa
dc.source.bibliographicCitationfor the European Society for Blood and Marrow Transplantation EBMT, Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant [Internet]. 2014 Jun [cited 2020 Jun 1];49(6):744–50. Available from: http://www.nature.com/articles/bmt201455spa
dc.source.bibliographicCitationKalwak K, Gorczynska E, Toporski J, Turkiewicz D, Slociak M, Ussowicz M, et al. Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery. Br J Haematol [Internet]. 2002 Jul [cited 2020 Jun 1];118(1):74–89. Available from: http://doi.wiley.com/10.1046/j.1365-2141.2002.03560.xspa
dc.source.bibliographicCitationBrown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, et al. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20;115(20):4111–9.spa
dc.source.bibliographicCitationPodgorny PJ, Pratt LM, Liu Y, Dharmani-Khan P, Luider J, Auer-Grzesiak I, et al. Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation [Internet]. 2016 Jan [cited 2020 Jun 1];22(1):37–46. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879115006084spa
dc.source.bibliographicCitationBerger M, Figari O, Bruno B, Raiola A, Dominietto A, Fiorone M, et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant [Internet]. 2008 Jan [cited 2020 Jun 1];41(1):55–62. Available from: http://www.nature.com/articles/1705870spa
dc.source.bibliographicCitationFedele R, Martino M, Garreffa C, Messina G, Console G, Princi D, et al. The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus. 2012 Apr;10(2):174–80.spa
dc.source.bibliographicCitationBartelink IH, Belitser SV, Knibbe CAJ, Danhof M, de Pagter AJ, Egberts TCG, et al. Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children. Biology of Blood and Marrow Transplantation [Internet]. 2013 Feb [cited 2020 Jun 1];19(2):305–13. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879112004260spa
dc.source.bibliographicCitationElfeky R, Lazareva A, Qasim W, Veys P. Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. Expert Review of Clinical Immunology [Internet]. 2019 Jul 3 [cited 2020 Jun 1];15(7):735–51. Available from: https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1612746spa
dc.source.bibliographicCitationKim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, et al. Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. Biology of Blood and Marrow Transplantation [Internet]. 2015 May [cited 2020 Jun 1];21(5):873–80. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879115000592spa
dc.source.bibliographicCitationRigoni L, Scroferneker ML, Pitombeira BS, Ottoni E, Paz A, Fischer G, et al. Importance of early absolute lymphocyte count after allogeneic stem cell transplantation: a retrospective study. Transplant Proc. 2015 Mar;47(2):511–6.spa
dc.source.bibliographicCitationBayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, et al. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation [Internet]. 2016 Mar [cited 2020 Jun 1];22(3):505–13. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879115007090spa
dc.source.bibliographicCitationBurke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, et al. Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation [Internet]. 2011 Jun [cited 2020 Jun 1];17(6):831–40. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879110003794spa
dc.source.bibliographicCitationKobulnicky DJ, Sabo RT, Sharma S, Shubar Ali AS, Kobulnicky KM, Roberts CH, et al. The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation. Leukemia & Lymphoma [Internet]. 2018 Dec 2 [cited 2020 Jun 1];59(12):2973–81. Available from: https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1452216spa
dc.source.bibliographicCitationIshaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant [Internet]. 2008 Feb [cited 2020 Jun 1];41(3):245–52. Available from: http://www.nature.com/articles/1705891spa
dc.source.bibliographicCitationHan DK, Baek HJ, Kim SY, Hwang TJ, Kook H. Implication of Early Lymphocyte Recovery after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Leukemia. Yonsei Med J [Internet]. 2013 [cited 2020 Jun 1];54(1):62. Available from: https://eymj.org/DOIx.php?id=10.3349/ymj.2013.54.1.62spa
dc.source.bibliographicCitationTurki AT, Lamm W, Schmitt C, Bayraktar E, Alashkar F, Metzenmacher M, et al. Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. Ann Hematol [Internet]. 2019 Feb [cited 2020 Jun 1];98(2):491–500. Available from: http://link.springer.com/10.1007/s00277-018-3538-8spa
dc.source.bibliographicCitationAkahoshi Y, Kimura S, Gomyo A, Hayakawa J, Tamaki M, Harada N, et al. Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome. Hematological Oncology [Internet]. 2018 Feb [cited 2020 Jun 1];36(1):276–84. Available from: http://doi.wiley.com/10.1002/hon.2427spa
dc.source.bibliographicCitationMoneib H, Hafez H, Abdalla A, Hassanain O, Lehmann L, Haddad A el. Day +100 Platelet Count Predicts Survival After Allogeneic Hematopoietic Stem-Cell Transplantation in Children With Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia [Internet]. 2019 May [cited 2020 Jun 1];19(5):e221–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2152265018305858spa
dc.source.bibliographicCitationTuthill M, Hatzimichael. Hematopoietic stem cell transplantation. SCCAA [Internet]. 2010 Aug [cited 2020 Jun 1];105. Available from: http://www.dovepress.com/hematopoietic-stem-cell-transplantation-peer-reviewed-article-SCCAAspa
dc.source.bibliographicCitationBrown VI, editor. Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist [Internet]. Cham: Springer International Publishing; 2018 [cited 2020 Jun 1]. Available from: http://link.springer.com/10.1007/978-3-319-63146-2spa
dc.source.bibliographicCitationChoo SY. The HLA System: Genetics, Immunology, Clinical Testing, and Clinical Implications. Yonsei Med J [Internet]. 2007 [cited 2020 Jun 1];48(1):11. Available from: https://eymj.org/DOIx.php?id=10.3349/ymj.2007.48.1.11spa
dc.source.bibliographicCitationPeters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial. JCO [Internet]. 2015 Apr 10 [cited 2020 Jun 1];33(11):1265–74. Available from: http://ascopubs.org/doi/10.1200/JCO.2014.58.9747spa
dc.source.bibliographicCitationBuckley RH, Schiff SE, Schiff RI, Markert ML, Williams LW, Roberts JL, et al. Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined Immunodeficiency. N Engl J Med [Internet]. 1999 Feb 18 [cited 2020 Jun 2];340(7):508–16. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199902183400703spa
dc.source.bibliographicCitationKhouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O’Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. JCO [Internet]. 1998 Aug [cited 2020 Jun 1];16(8):2817–24. Available from: http://ascopubs.org/doi/10.1200/JCO.1998.16.8.2817spa
dc.source.bibliographicCitationZhang M-J, Davies SM, Camitta BM, Logan B, Tiedemann K, Eapen M. Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation [Internet]. 2012 Aug [cited 2020 Jun 1];18(8):1204–10. Available from: https://linkinghub.elsevier.com/retrieve/pii/S108387911200033Xspa
dc.source.bibliographicCitationBolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant [Internet]. 2004 Feb [cited 2020 Jun 1];33(4):419–23. Available from: http://www.nature.com/articles/1704330spa
dc.source.bibliographicCitationAkahoshi Y, Kanda J, Gomyo A, Hayakawa J, Komiya Y, Harada N, et al. Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation [Internet]. 2016 Sep [cited 2020 Jun 1];22(9):1678–83. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879116301343spa
dc.source.bibliographicCitationImamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune Reconstitution and Tolerance after Allogeneic Hematopoietic Stem Cell Transplantation. Hematology [Internet]. 2003 Jan [cited 2020 Jun 1];8(1):19–26. Available from: https://www.tandfonline.com/doi/full/10.1080/1024533031000072045spa
dc.source.bibliographicCitationFerrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. The Lancet [Internet]. 2009 May [cited 2020 Jun 1];373(9674):1550–61. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673609602373spa
dc.source.bibliographicCitationZeiser R, Blazar BR. Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy. Longo DL, editor. N Engl J Med [Internet]. 2017 Nov 30 [cited 2020 Jun 1];377(22):2167–79. Available from: http://www.nejm.org/doi/10.1056/NEJMra1609337spa
dc.source.bibliographicCitationKuba A, Raida L. Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence. Mediators of Inflammation [Internet]. 2018 [cited 2020 Jun 1];2018:1–13. Available from: https://www.hindawi.com/journals/mi/2018/9451950/spa
dc.source.bibliographicCitationHe FC, Holtan SG. Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions. Curr Hematol Malig Rep [Internet]. 2018 Feb [cited 2020 Jun 1];13(1):44–52. Available from: http://link.springer.com/10.1007/s11899-018-0433-2spa
dc.source.bibliographicCitationMacDonald KPA, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus-host disease. Journal of Clinical Investigation [Internet]. 2017 Jun 30 [cited 2020 Jun 1];127(7):2452–63. Available from: https://www.jci.org/articles/view/90593spa
dc.source.bibliographicCitationZeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. Longo DL, editor. N Engl J Med [Internet]. 2017 Dec 28 [cited 2020 Jun 1];377(26):2565–79. Available from: http://www.nejm.org/doi/10.1056/NEJMra1703472spa
dc.source.bibliographicCitationMacDonald KPA, Betts BC, Couriel D. Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation [Internet]. 2018 Jan [cited 2020 Jun 1];24(1):19–26. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879117307620spa
dc.source.bibliographicCitationChow EJ, Cushing-Haugen KL, Cheng G-S, Boeckh M, Khera N, Lee SJ, et al. Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. JCO [Internet]. 2017 Jan 20 [cited 2020 Jun 1];35(3):306–13. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.68.8457spa
dc.source.bibliographicCitationAtsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, et al. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation [Internet]. 2016 Sep [cited 2020 Jun 1];22(9):1702–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879116301112spa
dc.source.bibliographicCitationBhatia S, Davies SM, Scott Baker K, Pulsipher MA, Hansen JA. NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Etiology and Pathogenesis of Late Effects after HCT Performed in Childhood—Methodologic Challenges. Biology of Blood and Marrow Transplantation [Internet]. 2011 Oct [cited 2020 Jun 1];17(10):1428–35. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879111002904spa
dc.source.bibliographicCitationThoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, et al. Peripheral Blood Lymphocyte and Monocyte Recovery and Survival in Acute Leukemia Postmyeloablative Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation [Internet]. 2012 Apr [cited 2020 Jun 5];18(4):600–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1083879111003405spa
dc.source.bibliographicCitationDeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, et al. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transplant [Internet]. 2013 May [cited 2020 Jun 5];48(5):708–14. Available from: http://www.nature.com/articles/bmt2012211spa
dc.source.bibliographicCitationYamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H. Lymphocyte recovery on day 100 after allogeneic hematopoietic stem cell transplant predicts non-relapse mortality in patients with acute leukemia or myelodysplastic syndrome. Leukemia & Lymphoma [Internet]. 2014 May [cited 2020 Jun 5];55(5):1113–8. Available from: http://www.tandfonline.com/doi/full/10.3109/10428194.2013.823491spa
dc.source.bibliographicCitationMorando J, Fortier SC, Pasquini R, Zanis Neto J, Bonfim CMS. Early lymphocyte recovery as a predictor of outcome, including relapse, after hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2012;34(6):430–5.spa
dc.source.bibliographicCitationBae KW, Kim BE, Koh KN, Im HJ, Seo JJ. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children. Korean J Hematol [Internet]. 2012 [cited 2020 Jun 5];47(1):44. Available from: https://synapse.koreamed.org/DOIx.php?id=10.5045/kjh.2012.47.1.44spa
dc.source.bibliographicCitationNiehues T, Rocha V, Filipovich AH, Chan KW, Porcher R, Michel G, et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children - a Eurocord analysis. Br J Haematol [Internet]. 2001 Jul [cited 2020 Jun 5];114(1):42–8. Available from: http://doi.wiley.com/10.1046/j.1365-2141.2001.02900.xspa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectTrasplante de progenitores hematopoyéticos PHspa
dc.subjectTrasplante alogénicospa
dc.subjectNiñosspa
dc.subjectTrombocitopeniaspa
dc.subjectPronósticospa
dc.subjectSobrevidaspa
dc.subjectEnfermedad injerto contra huésped EICHspa
dc.subject.ddcEnfermedadesspa
dc.subject.keywordHematopoietic Stem Cell Transplantationspa
dc.subject.keywordTransplantationeng
dc.subject.keywordThrombocytopeniaspa
dc.subject.keywordPrognosisspa
dc.subject.keywordSurvival Analysisspa
dc.subject.keywordGraft vs Host Diseasespa
dc.titleRelación entre el conteo plaquetario y linfocitario y la sobrevida en pacientes menores de 18 años con trasplante alogénico de células madre hematopoyéticasspa
dc.title.TranslatedTitleRelationship between platelet and lymphocyte count and survival in patients under 18 years of age with allogeneic hematopoietic stem cell transplantationeng
dc.typebachelorThesiseng
dc.type.documentDescriptivo observacional retrospectivospa
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
RELACIoN-ENTRE-EL-CONTEO-PLAQUETARIO-Y-LINFOCITARIO-.pdf
Tamaño:
1.12 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Epidemiología